Sanofi US
NEWS
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease.
Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Asthma patients may soon have a new treatment option.
JOBS
IN THE PRESS